Capas, Nito A.
HRN: 21-74-92 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/06/2022
CO-AMOXICLAV 625MG (TAB)
08/06/2022
08/14/2022
PO
625mg
BID
Uncomplicated UTI
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes